Pavlov S.V., Kotlyarevska E.V., Svitlytska O.A., Kiknadze T.I.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The aim of the study was to evaluate the treatment effectiveness in patients with interstitial pneumonia after coronavirus disease COVID-19 using infusion therapy of L-arginine aspartate for 10 days according to neutrophillymphocyte ratio (NLR), serum fibrinogen and D‑dimer ratio. The mean age of patients was 64 years (52; 72). The observation groups did not differ in age and gender (p>0.05). The examined patients had concomitant diseases: 13.9 % of patients had coronary heart disease, 48.6 % of patients had hypertension, COPD and bronchial asthma were in 5.6 % and 6.9 % of patients, diabetes mellitus – in 22.2 % of patients and 26.4 % of patients were obese. The composition of comorbidities did not differ between the observation groups (p>0.05). In the patients that were studied, the NLR increased to 3.43, which reflects the strength of stress and/or systemic inflammation. The level of NLR has positive correlations with D‑dimer (r=+0.64, p<0.05), C‑reactive protein (CRP) (r=+0.66, p<0.05) and fibrinogen (r=+0.56, p<0.05). At the background of treatment after 10 days, the level of NLR in the group of patients receiving L-arginine hydrochloride (group I) was 14.8 % lower than in patients of group II (patients not receiving L‑arginine hydrochloride) (p<0.05). Patients in group I had a significant decrease in serum CRP concentration by 26.9 % (p<0.05), which is less than in group II by 21.6 % (p<0.05); fibrinogen level by 40.4 % (p <0.05), at the same time in patients of group II the level of fibrinogen at the end of the treatment was 22.2 % higher than in group I (p<0.05). At the end of therapy, there was a significant decrease in the concentration of D‑dimer in group I by 40.0 % (p<0.05), which exceeded the serum level in patients of group II at the end of therapy by 25.2 % (p<0.05). In the pathogenetic therapy of interstitial pneumonia after coronavirus disease COVID-19 it is advisable to use L-arginine aspartate to reduce the activity of inflammatory processes, improve the hemostasis system.

interstitial pneumonia, neutrophil-lymphocyte ratio, fibrinogen, D-dimer, L-arginine aspartate.

1. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. Int J Mol Sci. 2016 Dec 16;17(12):2120. DOI: 10.3390/ijms17122120.
2. Feshchenko YuI, Dzyublik OYa, Dzyublik MN. Nehospitalʹna pnevmoniya, asotsiyovana z COVID-19: pohlyad na likuvannya. Ukrayinsʹkyy pulʹmonolohichnyy zhurnal. 2020;2:5–12. DOI: 10.31215/2306–4927–2020–108–2–5–12. [in Ukrainian].
3. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020 Jun 25;58(7):1021–1028. DOI: 10.1515/cclm-2020–0369.
4. Kiryeyeva TV, Basina BO. Rolʹ neytrofilʹno-limfotsytarnoho spivvidnoshennya pry zahostrennyakh khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ. Ukr. pulʹmonol. zhurnal. Dodatok. 2018;3. [in Ukrainian].
5. Kondratyuk VM. Znachennya neytrofilʹno-limfotsytarnoho spivvidnoshennya dlya prohnozuvannya zatrymky zahoyennya boyovykh poranenʹ. Travma. 2016;17;5:67–71. DOI: http://dx.doi.org/10.22141/1608–1706.5.17.2016.83878. [in Ukrainian].
6. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017 Jan;137:82–92. DOI: 10.1016/j.antiviral.2016.11.006.
7. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 May;27(5):1451–1454. DOI: 10.1038/s41418–020–0530–3.
8. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):533–535. DOI: 10.1038/s41423–020–0402–2.
9. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020 Jul;84:106504. DOI: 10.1016/j.intimp.2020.106504.
10. Berhane M, Melku M, Amsalu A, Enawgaw B, Getaneh Z, Asrie F. The Role of Neutrophil to Lymphocyte Count Ratio in the Differential Diagnosis of Pulmonary Tuberculosis and Bacterial Community-Acquired Pneumonia: a Cross-Sectional Study at Ayder and Mekelle Hospitals, Ethiopia. Clin Lab. 2019 Apr 1;65(4). DOI: 10.7754/Clin.Lab.2018.180833.
11. Liu H, Zhang H, Wan G, Sang Y, Chang Y, Wang X, et al. Neutrophil-lymphocyte ratio: a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2014 Jul;21(7):499–507. DOI: 10.1111/jvh.12160.
12. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020 Jun;95(6): E 131-E 134. DOI: 10.1002/ajh.25774.
13. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020 May 20;18(1):206. DOI: 10.1186/s12967–020–02374–0.
14. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802–810. DOI: 10.1001/jamacardio. 2020.0950.
15. Mazza MG, Lucchi S, Rossetti A, Clerici M. Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: A meta-analysis and systematic review. World J Biol Psychiatry. 2020 Jun;21(5):326–338. DOI: 10.1080/15622975.2019.1583371.
16. Darooghegi Mofrad M, Milajerdi A, Koohdani F, Surkan PJ, Azadbakht L. Garlic Supplementation Reduces Circulating C-reactive Protein, Tumor Necrosis Factor, and Interleukin-6 in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Nutr. 2019 Apr 1;149(4):605–618. DOI: 10.1093/jn/nxy310.
17. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019 Feb 7;133(6):511–520. DOI: 10.1182/blood-2018–07–818211.
18. Eljilany I, Elzouki AN. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag. 2020 Nov 13;16:455–462. DOI: 10.2147/VHRM.S 280962.
19. Netyazhenko VZ, Malʹchevsʹka TY, Valihura MS. Vplyv preparatu Tivortin® aspartat na trombotsytarno-plazmovyy hemostaz u patsiyentiv iz hipertonichnoyu khvoroboyu. Ukr. med. Chasopys. 2016;3(113):89–91 [in Ukrainian].
20. Nazarian B, Fazeli Moghadam E, Asbaghi O, Zeinali Khosroshahi M, Choghakhori R, Abbasnezhad A. Effect of l-arginine supplementation on C‑reactive protein and other inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2019 Dec;47:102226. DOI: 10.1016/j.ctim.2019.102226.
21. Fiorentino G, Coppola A, Izzo R, Annunziata A, Bernardo M, Lombardi A, et al. Effects of adding L-arginine orally to standard therapy in patients with COVID‑19: A randomized, double-­blind, placebo-­controlled, parallel-­group trial. Results of the first interim analysis. EClinicalMedicine. 2021 Oct;40:101125. DOI: 10.1016/j.eclinm.2021.101125.
22. Valihura MS. Vplyv L-arhininu aspartat na plazmovyy hemostaz u patsiyentiv z hipertonichnoyu khvoroboyu II stadiyi iz suputnʹoyu hiperurykemiyeyu. Semeynaya medytsyna. 2018;5(79):75–79. DOI: https://doi.org/10.30841/ 2307–5112.5.2018.166716. [in Ukrainian].
23. Lynnyk MI, Ihnatʹyeva VI, Humenyuk HL, Tarasenko OR, Opimakh SH, Chumak IV, et al. Otsinka efektyvnosti likuvannya khvorykh na nehospitalʹnu pnevmoniyu virusnoyi etiolohiyi (COVID-19) iz zastosuvannyam syndromno-patohenetychnoyi maloobʺyemnoyi infuziynoyi terapiyi za danymy kompʺyuternoyi tomohrafiyi. Infusion & chemotherapy. 2021;2:31–38. DOI: 10.32902/2663–0338– 2021–2–31–38. [in Ukrainian].
24. Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. Front Microbiol. 2019 Dec 3;10:2752. DOI: 10.3389/fmicb.2019. 02752.
25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–513. DOI: 10.1016/S 0140–6736(20)30211–7.
26. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762–768. DOI: 10.1093/cid/ciaa248.
27. King AH, Mehkri O, Rajendram P, Wang X, Vachharajani V, Duggal A. A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019. Crit Care Explor. 2021 May 17;3(5): e0444. DOI: 10.1097/CCE.0000000000000444.

«Bulletin of problems biology and medicine» Issue 2 Part 1 (164), 2022 year, 225-239 pages, index UDK 616.24–002.17:[616.98:578.834.1COV]-036.8–06]-092–074/-076:577.1

10.29254/2077-4214-2022-2-1-164-225-239